DE69131349T2 - Phospholipid-beschichtete mikrokristalle: injizierbare formulierungen wasserlöslicher arzneimittel - Google Patents

Phospholipid-beschichtete mikrokristalle: injizierbare formulierungen wasserlöslicher arzneimittel

Info

Publication number
DE69131349T2
DE69131349T2 DE69131349T DE69131349T DE69131349T2 DE 69131349 T2 DE69131349 T2 DE 69131349T2 DE 69131349 T DE69131349 T DE 69131349T DE 69131349 T DE69131349 T DE 69131349T DE 69131349 T2 DE69131349 T2 DE 69131349T2
Authority
DE
Germany
Prior art keywords
phospholipid
water
coated
proteins
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131349T
Other languages
English (en)
Other versions
DE69131349D1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma-Logic Inc
Original Assignee
Pharma-Logic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma-Logic Inc filed Critical Pharma-Logic Inc
Application granted granted Critical
Publication of DE69131349D1 publication Critical patent/DE69131349D1/de
Publication of DE69131349T2 publication Critical patent/DE69131349T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
DE69131349T 1990-04-26 1991-04-23 Phospholipid-beschichtete mikrokristalle: injizierbare formulierungen wasserlöslicher arzneimittel Expired - Lifetime DE69131349T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/514,012 US5091188A (en) 1990-04-26 1990-04-26 Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
PCT/US1991/002804 WO1991016068A1 (en) 1990-04-26 1991-04-23 Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs

Publications (2)

Publication Number Publication Date
DE69131349D1 DE69131349D1 (de) 1999-07-22
DE69131349T2 true DE69131349T2 (de) 1999-11-18

Family

ID=24045456

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131349T Expired - Lifetime DE69131349T2 (de) 1990-04-26 1991-04-23 Phospholipid-beschichtete mikrokristalle: injizierbare formulierungen wasserlöslicher arzneimittel

Country Status (16)

Country Link
US (2) US5091188A (de)
EP (1) EP0533690B1 (de)
JP (1) JP3261129B2 (de)
KR (1) KR0159114B1 (de)
AT (1) ATE181234T1 (de)
AU (1) AU7852891A (de)
CA (1) CA2078990C (de)
DE (1) DE69131349T2 (de)
DK (1) DK0533690T3 (de)
ES (1) ES2134776T3 (de)
GR (1) GR3030825T3 (de)
MX (1) MX25532A (de)
RU (1) RU2100030C1 (de)
TW (1) TW203559B (de)
WO (1) WO1991016068A1 (de)
ZA (1) ZA913122B (de)

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
WO1993015731A1 (en) * 1992-02-14 1993-08-19 Robert Lamb Phosphate derivatives of vitamin e to protect cells from effects of aging and injury
DE4221268C2 (de) * 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030073642A1 (en) * 1993-02-22 2003-04-17 American Bioscience, Inc. Methods and formulations for delivery of pharmacologically active agents
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
DE19609538A1 (de) * 1996-03-11 1997-09-18 Basf Ag Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung
DE4322158C2 (de) * 1993-07-03 1997-04-10 Rhone Poulenc Rorer Gmbh Phospholipidische Zusammensetzung sowie Verwendung einer derartigen Zusammensetzung
US5393461A (en) * 1993-10-04 1995-02-28 Rtd Corporation Preparation of stable aqueous emulsions of water-insoluble particles
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
EP0810853B1 (de) 1995-02-24 2004-08-25 Elan Pharma International Limited Nanopartikel-dispersionen enthaltende aerosole
DE19511276C2 (de) * 1995-03-27 1999-02-18 Immuno Ag Adjuvans auf der Basis kolloidaler Eisenverbindungen
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
AU709262B2 (en) * 1995-10-17 1999-08-26 Board Of Regents, The University Of Texas System Insoluble drug delivery
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
RO120603B1 (ro) 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6331311B1 (en) 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
FR2757768B1 (fr) * 1996-12-27 1999-04-02 Biovector Therapeutics Sa Vecteur particulaire homeocharge et composition pharmaceutique ou cosmetique le contenant
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
WO1998047492A1 (en) * 1997-04-18 1998-10-29 Vertex Pharmaceuticals Incorporated Nanosized aspartyl protease inhibitors
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
CA2294981C (en) * 1997-06-27 2012-04-03 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
CN1285753A (zh) * 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
CA2320807C (en) * 1998-02-11 2011-01-18 Research Triangle Pharmaceuticals Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
GB9814507D0 (en) * 1998-07-03 1998-09-02 Univ Southampton A method and apparatus for controlling pests
US7343710B2 (en) * 1998-07-03 2008-03-18 I.D.A Limited Method and apparatus for controlling pests
IL141095A0 (en) * 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
WO2000023592A2 (en) * 1998-10-19 2000-04-27 Powderject Vaccines, Inc. Minimal promoters and uses thereof
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1133281A1 (de) * 1998-11-20 2001-09-19 RTP Pharma Inc. Dispergierbare mit phospholipid stabilisierte mikropartikel
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
KR100359252B1 (ko) * 1999-12-21 2002-11-04 주식회사 엘지생명과학 항원을 포함하는 고체상 미세입자 및 이를 포함하는 제제
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
AU3606100A (en) * 1999-02-26 2000-09-14 Idexx Laboratories, Inc. Methods for administering pharmacologically active compounds to vertebrates
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6551842B1 (en) 1999-03-26 2003-04-22 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
PL364983A1 (en) 1999-08-24 2004-12-27 Teva Pharmaceutical Industries, Ltd. A vaccine composition and method of using the same
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
CA2383233C (en) * 1999-09-21 2010-06-08 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US6919009B2 (en) * 1999-10-01 2005-07-19 Nanoplex Technologies, Inc. Method of manufacture of colloidal rod particles as nanobarcodes
US7225082B1 (en) 1999-10-01 2007-05-29 Oxonica, Inc. Colloidal rod particles as nanobar codes
US7045049B1 (en) * 1999-10-01 2006-05-16 Nanoplex Technologies, Inc. Method of manufacture of colloidal rod particles as nanobar codes
US20040209376A1 (en) * 1999-10-01 2004-10-21 Surromed, Inc. Assemblies of differentiable segmented particles
US20040178076A1 (en) * 1999-10-01 2004-09-16 Stonas Walter J. Method of manufacture of colloidal rod particles as nanobarcodes
US20050032226A1 (en) * 1999-10-01 2005-02-10 Natan Michael J. Encoded nanoparticles in paper manufacture
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
CN1313080C (zh) 2000-04-20 2007-05-02 斯凯伊药品加拿大公司 改进的水不溶性药物粒子的制备方法
NZ522896A (en) 2000-05-10 2004-05-28 Skyepharma Canada Inc Media milling
JP2003535884A (ja) 2000-06-16 2003-12-02 スカイファーマ・カナダ・インコーポレーテッド プロポフォールの改善された注射可能な分散物
AU2001288471B2 (en) 2000-08-31 2006-03-02 Rtp Pharma Inc. Milled particles
DE10145910A1 (de) * 2000-09-18 2002-06-20 Registrar University Of Delhi Ophtalmologische Formulierung mit verlangsamter Freisetzung und langer Verweildauer sowie Herstellungsverfahren hierfür
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
KR100884493B1 (ko) 2000-12-19 2009-02-18 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 위장관을 보호하고 개선된 치료학적 활성을 제공하기위한, 레시틴 오일과 ｎｓａｉｄ의 제형을 사용하는 방법및 조성물
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6497896B2 (en) 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US6509027B2 (en) 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6534088B2 (en) * 2001-02-22 2003-03-18 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
WO2002074247A2 (en) * 2001-03-19 2002-09-26 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
JP2004524368A (ja) * 2001-03-27 2004-08-12 フェアーズ ファーマシューティカル リサーチ エヌ．ヴェー． 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物
US20020146745A1 (en) * 2001-04-03 2002-10-10 Surromed, Inc. Methods and reagents for multiplexed analyte capture, surface array self-assembly, and analysis of complex biological samples
CA2441108A1 (en) * 2001-04-05 2002-10-17 Universite Laval Process for making delivery matrix and uses thereof
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
IL160570A0 (en) * 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
KR100836035B1 (ko) * 2002-02-19 2008-06-09 (주)아모레퍼시픽 포화 및 불포화 레시틴 함유 나노에멀젼 및 이를 함유하는화장료 조성물
ATE343376T1 (de) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7101566B2 (en) * 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US7838034B2 (en) * 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
EP2298806A1 (de) 2002-10-16 2011-03-23 Purdue Pharma L.P. Antikörper, die an zellassoziiertes CA 125/0722P binden, und Verfahren zu deren Anwendung
ATE411010T1 (de) * 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4880449B2 (ja) 2003-03-04 2012-02-22 リオトロピック セラピュティックス アイエヌシー． ダントロレンを用いる治療
WO2004113869A2 (en) * 2003-06-17 2004-12-29 Surromed, Inc. Labeling and authentication of metal objects
DE10327839A1 (de) * 2003-06-20 2005-01-05 Arvinmeritor Gmbh Fahrzeugdachmodul
BRPI0414970A2 (pt) * 2003-06-24 2012-12-11 Baxter Int método para transporte de drogas ao cérebro
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US20080051373A1 (en) * 2003-07-31 2008-02-28 The Board Of Regents Of The University Of Texas System Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
JP2005097295A (ja) * 2003-09-01 2005-04-14 Wakunaga Pharmaceut Co Ltd ビタミン安定液剤
ES2394208T3 (es) 2003-09-22 2013-01-23 Baxter International Inc. Esterilización a alta presión para la esterilización definitiva de preparaciones farmacéuticas y productos médicos
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
JP3903061B2 (ja) * 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
CN1913871A (zh) * 2004-01-29 2007-02-14 巴克斯特国际公司 用于提高中枢神经系统投递的抗－逆转录病毒药剂的纳米悬浮液
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
EP1730516A1 (de) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Verfahren und vorrichtung zur bewertung pharmazeutischer zusammensetzungen
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
RU2006146555A (ru) * 2004-05-28 2008-07-20 Шеринг Копрорейшн (Us) Инъецируемые фармацевтические композиции позаконазола со стабилизированными частицами
AU2005255039A1 (en) * 2004-06-15 2005-12-29 Baxter Healthcare S.A. Ex-vivo application of solid microparticulate therapeutic agents
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
CA2628630A1 (en) * 2005-11-15 2007-05-24 Baxter International Inc. Compositions of lipoxygenase inhibitors
AU2007233155B2 (en) 2006-03-29 2012-04-26 Scitech Development Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
WO2008054508A2 (en) * 2006-04-13 2008-05-08 Alza Corporation Stable nanosized amorphous drug
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
WO2008013822A2 (en) * 2006-07-26 2008-01-31 The Board Of Regent Of The University Of Texas System Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US20110021592A1 (en) * 2006-09-14 2011-01-27 Shlomo Magdassi Organic nanoparticles obtained from microemulsions by solvent evaporation
AR063704A1 (es) * 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US20080279784A1 (en) * 2007-05-07 2008-11-13 Questcor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009094460A2 (en) 2008-01-22 2009-07-30 Vapogenix, Inc. Volatile anesthetic compositions and methods of use
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
EP2259798B1 (de) 2008-03-05 2013-12-11 Baxter International Inc. Zusammensetzungen und verfahren zur wirkstofffreisetzung
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
AU2009253780B2 (en) 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
CA2748034A1 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010129686A1 (en) * 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
AU2011336467A1 (en) 2010-12-01 2013-07-04 Spinal Modulation, Inc. Agent delivery systems for selective neuromodulation
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN107737100A (zh) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 苯二氮卓组合物的投与
JP6368645B2 (ja) 2011-09-29 2018-08-01 ピーエルエックス オプコ インコーポレーテッド 胃腸管に沿った医薬の標的化放出のためのｐＨ依存性担体、それによる組成物、ならびにこれらの製造および使用
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
CA3170184A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
WO2014143964A2 (en) 2013-03-15 2014-09-18 Vapogenix, Inc. Novel analgesic compositions
RU2541156C1 (ru) * 2013-07-09 2015-02-10 Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии" Трансдермальное антигельминтное средство на основе кремнийорганических ниосом с альбендазолом
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
AU2021244695A1 (en) 2020-03-26 2022-11-10 Plx Opco Inc. Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
CN116687847B (zh) * 2023-06-26 2024-03-29 石家庄四药有限公司 一种药物微晶注射液及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4298594A (en) * 1978-04-14 1981-11-03 Arthur D. Little, Inc. Xenobiotic delivery vehicles, method of forming them and method of using them
DE2856333C2 (de) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
US4421747A (en) * 1978-12-27 1983-12-20 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
US4378354A (en) * 1978-12-27 1983-03-29 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
DE2914788A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
JPS562353A (en) * 1979-06-20 1981-01-12 Ricoh Co Ltd Novel disazo compound and its preparation
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
AR220263A1 (es) * 1980-02-19 1980-10-15 Bago Lab Sa Procedimiento para obtener una preparacion inyectable de sulfonamida potenciada de baja irritabilidad
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US5030453A (en) * 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
JPS6176414A (ja) * 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
JPH0617309B2 (ja) * 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
WO1987004592A1 (en) * 1986-02-10 1987-08-13 Liposome Technology, Inc. Controlled-release liposome delivery system
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
JPS62278241A (ja) * 1986-05-26 1987-12-03 Shoei Kagaku Kogyo Kk ボンデイングワイヤ
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
DK175531B1 (da) * 1986-12-15 2004-11-22 Nexstar Pharmaceuticals Inc Leveringsvehikel med amphiphil-associeret aktiv bestanddel
US4839111A (en) * 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations

Also Published As

Publication number Publication date
US5091188A (en) 1992-02-25
MX25532A (es) 1993-10-01
CA2078990A1 (en) 1991-10-27
EP0533690A4 (en) 1993-04-14
DK0533690T3 (da) 1999-11-22
TW203559B (de) 1993-04-11
GR3030825T3 (en) 1999-11-30
USRE35338E (en) 1996-09-24
EP0533690A1 (de) 1993-03-31
DE69131349D1 (de) 1999-07-22
JPH05507685A (ja) 1993-11-04
ZA913122B (en) 1992-04-29
ATE181234T1 (de) 1999-07-15
WO1991016068A1 (en) 1991-10-31
JP3261129B2 (ja) 2002-02-25
EP0533690B1 (de) 1999-06-16
AU7852891A (en) 1991-11-11
KR0159114B1 (ko) 1998-12-01
RU2100030C1 (ru) 1997-12-27
ES2134776T3 (es) 1999-10-16
CA2078990C (en) 2002-06-04

Similar Documents

Publication Publication Date Title
DE69131349D1 (de) Phospholipid-beschichtete mikrokristalle: injizierbare formulierungen wasserlöslicher arzneimittel
US5773006A (en) Lipsome containing IL-2
Kao et al. Interactions of liposomes with the reticuloendothelial system effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles
Seiler et al. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection
ATE206046T1 (de) Inhalationspräparate
RU95112536A (ru) Способы пульсирующего системного введения активного фрагмента паратиреоидного гормона (ртн) и фармацевтические композиции, содержащие биологически активный n-концевой фрагмент паратиреоидного гормона (ртн)
ATE131042T1 (de) Pharmakologische zubereitung, enthaltend polyelektrolytkomplexe in mikropartikulärer form und mindestens einen wirkstoff.
EP0458894A4 (de) Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung.
KR890701093A (ko) 아라키돈산 대사물질 관련 리포좀 제조방법 및 그 제제
US5741517A (en) Water-containing liposome system
EP0728476B1 (de) Liposomenzusammensetzung
CA2050679C (en) Preparation of liposome and lipid complex compositions
JPH0696515B2 (ja) 小胞の貯蔵方法
CA2200550A1 (en) Chitosan induced immunopotentiation
Van Rooijen et al. Liposomes in immunology: the immune response against antigen-containing liposomes
Bergers et al. Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines
GR3018064T3 (en) Aqueous phospholipid vesicle dispersion, process for its manufacture and use thereof.
ATE87467T1 (de) Pharmazeutische zubereitung.
Khor et al. Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis.
Sone et al. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state
Serdyuk et al. Shape and compactness of the isolated ribosomal 16 S RNA and its complexes with ribosomal proteins
Kleinerman et al. Intracellular activation of human and rodent macrophages by human lymphokines encapsulated in liposomes
Gurari-Rotman et al. Encapsulation of human fibroblast interferon activity in liposomes
CA2319599A1 (en) Delivery of immunogenic molecules via hbsag particles
Beatty et al. Liposome stimulation of anti-BSA antibody production in mice

Legal Events

Date Code Title Description
8364 No opposition during term of opposition